New Hope For Alzheimer’s Disease

Help for Alzheimer’s Disease.

Alzheimer’s Disease is a devastating disease that affects more than 25 million people worldwide. There is no cure, but there is new hope. Recent studies reveal new understanding of the root cause of Alzheimer’s. This has led to a major shift in research for a cure.

Until now, the prevailing view—called the amyloid beta theory—maintained that plaque build-up in the brain caused Alzheimer’s disease. However, we now know that the root cause of Alzheimer’s is not plaque: it’s the toxic oligomer—another form of beta amyloid. The toxic oligomer kills the brain cells which leads to Alzheimer’s and other neurodegenerative diseases.

ProMIS is dedicated to developing PMN310 as an effective therapy for Alzheimer’s disease by selectively targeting its root cause. New understanding of the amyloid beta theory could help deliver much needed medicine to the millions of people affected by this terrible disease.

Promis Neurosciences – offering real hope for an effective Alzheimer’s disease treatment.

More about ProMIS™ Neurosciences Inc.

ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and OTCQB (ticker symbol: ARFXF). ProMIS is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).

For more information on ProMIS Neurosciences Inc. (PMN:TSX) please fill out the form below.

Request Investor Kit